- The Wall Street Journal•6 minutes ago
The U.S. Food and Drug Administration said it has approved an insulin pump by medical device company Medtronic that automatically manages glucose levels within a target range.
- Associated Press•4 hours ago
WASHINGTON (AP) — Federal regulators have approved a first-of-a-kind "artificial pancreas," a device that can help some diabetes patients manage their disease by constantly monitoring their blood sugar and delivering insulin as needed.
- Reuters•5 hours ago
Medtronic Plc won U.S. approval on Wednesday for an "artificial pancreas" that is the first device to automatically deliver the right dose of insulin to patients with type 1 diabetes, freeing them from continually monitoring insulin levels throughout each day. The U.S. Food and Drug Administration, in its approval of the device, the MiniMed 670G, hailed it as a breakthrough. The device offers type 1 diabetics "greater freedom to live their lives without having to consistently and manually monitor baseline glucose levels and administer insulin," Dr. Jeffrey Shuren, director of the FDA's medical device division, said in a statement.
Medtronic plc (MDT)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||87.04 x 100|
|Ask||87.28 x 100|
|Day's Range||86.16 - 86.90|
|52wk Range||66.24 - 89.27|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||33.75|
|Avg Vol (3m)||4,267,532|
|Dividend & Yield||1.72 (1.99%)|